We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Luckily, the hiring process proceeded smoothly and Charles van Zyl joined as chief executive from Belgian pharma company UCB (BE:UCB) in 2023, while Joerg Hornstein has been in post as chief finance ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.

During a Senate HELP Committee hearing, RFK Jr. stated that President Trump is dedicated to bringing drug manufacturing "back ...

Robert F. Kennedy Jr., President Trump's nominee to lead HHS, spoke highly of GLP-1 drugs at a Senate confirmation hearing ...

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. , (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this annual letter from ...